KALA BIO, INC. Total Long-Term Debt
KALA BIO, INC. (KALA) had Total Long-Term Debt of $26.95 million as of 2025-09-30, per its 10-Q filed 2025-11-19.
Financial Statements › Balance Sheet › Liabilities
us-gaap:LongTermDebt · last filed 2026-04-15
- 2025-09-30: Long-term Debt $26.95M.
- 2025-06-30: Long-term Debt $26.95M.
- 2025-03-31: Long-term Debt $29.28M.
- 2024-12-31: Long-term Debt $29.28M.
| Period end | Long-term Debt |
|---|---|
| 2025-09-30 | $26.95M 10-Q · filed 2025-11-19 |
| 2025-06-30 | $26.95M 10-Q · filed 2025-08-08 |
| 2025-03-31 | $29.28M 10-Q · filed 2025-05-14 |
| 2024-12-31 | $29.28M 10-K · filed 2026-04-15 |
| 2024-09-30 | $33.96M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $33.96M 10-Q · filed 2024-08-06 |
| 2024-03-31 | $33.96M 10-Q · filed 2024-05-14 |
| 2023-12-31 | $33.96M 10-Q · filed 2024-11-12 |
| 2023-09-30 | $33.96M 10-Q · filed 2023-11-13 |
| 2023-06-30 | $33.96M 10-Q · filed 2023-08-04 |
| 2023-03-31 | $33.96M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $43.30M 10-Q · filed 2023-11-13 |
| 2021-12-31 | $80.00M 10-K · filed 2023-03-03 |
| 2020-12-31 | $75.00M 10-K · filed 2021-02-25 |
| 2019-12-31 | $75.00M 10-K · filed 2020-02-12 |
| 2018-12-31 | $75.00M 10-K · filed 2019-03-12 |
| 2018-09-30 | $20.00M 10-Q · filed 2018-11-08 |
| 2018-06-30 | $20.00M 10-Q · filed 2018-08-09 |
| 2018-03-31 | $20.00M 10-Q · filed 2018-05-10 |
| 2017-12-31 | $18.89M 10-K · filed 2018-04-02 |
| 2017-09-30 | $20.00M 10-Q · filed 2017-11-07 |
| 2017-06-30 | $10.00M 10-Q · filed 2017-08-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |